前收市價 | 3.1600 |
開市 | 3.1600 |
買盤 | 2.2000 |
賣出價 | 3.6000 |
拍板 | 25.00 |
到期日 | 2024-05-17 |
今日波幅 | 3.1600 - 3.1600 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 40 |
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99. Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone. […]
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.